Meet with the Researchers Behind Two New Exciting JM Drugs

Hear directly from the researchers behind two of the most exciting new treatments for juvenile myositis (JM). You’ll learn details of the new treatments and what these drugs could mean for you and your child with JM.

Featuring:

  • Dr. Kaveh Ardalan of Duke University
  • Dr. Travis Kinder of the NIH
  • Jim Minow, Cure JM Executive Director

What is Juvenile Myositis?

Juvenile myositis, including juvenile dermatomyositis and juvenile polymyositis, is a group of rare and life-threatening autoimmune diseases, in which the body’s immune system attacks its own cells and tissues.

Treatment Plans for Juvenile Myositis

A treatment plan is based on many factors, including the severity and expression of the juvenile dermatomyositis (JDM). Each case is different and the symptoms can change over time.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.